TY - JOUR
T1 - Serum levels of interleukin-10 in patients with diffuse large cell lymphoma
T2 - Lack of correlation with prognosis
AU - Cortes, Jorge E.
AU - Talpaz, Moshe
AU - Cabanillas, Fernando
AU - Seymour, John F.
AU - Kurzrock, Razelle
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1995/5/1
Y1 - 1995/5/1
N2 - Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor, has multiple effects on lymphoid development. In addition, it has been previously reported that serum levels of IL-10 correlate with failure- free and overall survival in patients with non-Hodgkin's lymphoma. In this study, we used a sensitive enzyme-linked immunosorbent assay specific for human IL-10 (lower limit of sensitivity, 5 pg/mL) to measure serum levels in 52 newly diagnosed patients with diffuse large cell lymphoma and at least one adverse prognostic feature who were subsequently treated in a uniform way. Lymphoma patients had significantly higher serum levels of IL-10 (median, 7.98 pg/mL; range, ≤5 to 27,143 pg/mL) than healthy volunteers (N = 50; median, ≤5 pg/mL; range, ≤5 to 19.21 pg/mL) (P = .0000012). Individuals with B symptoms had significantly higher serum levels of IL-10 than those without them (P = .03), but there was no correlation between IL-10 levels and any of the other prognostic variables analyzed, including age, lactic dehydrogenase, β2-microglobulin levels, performance status, bulky disease, Ann Arbor stage, or International Index score. More importantly, we found no correlation between IL-10 levels and the achievement of complete remission, nor with failure-free survival or overall survival. We conclude that in a uniform population of untreated patients with diffuse large cell lymphoma, serum levels of IL-10 do not appear to have any prognostic value.
AB - Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor, has multiple effects on lymphoid development. In addition, it has been previously reported that serum levels of IL-10 correlate with failure- free and overall survival in patients with non-Hodgkin's lymphoma. In this study, we used a sensitive enzyme-linked immunosorbent assay specific for human IL-10 (lower limit of sensitivity, 5 pg/mL) to measure serum levels in 52 newly diagnosed patients with diffuse large cell lymphoma and at least one adverse prognostic feature who were subsequently treated in a uniform way. Lymphoma patients had significantly higher serum levels of IL-10 (median, 7.98 pg/mL; range, ≤5 to 27,143 pg/mL) than healthy volunteers (N = 50; median, ≤5 pg/mL; range, ≤5 to 19.21 pg/mL) (P = .0000012). Individuals with B symptoms had significantly higher serum levels of IL-10 than those without them (P = .03), but there was no correlation between IL-10 levels and any of the other prognostic variables analyzed, including age, lactic dehydrogenase, β2-microglobulin levels, performance status, bulky disease, Ann Arbor stage, or International Index score. More importantly, we found no correlation between IL-10 levels and the achievement of complete remission, nor with failure-free survival or overall survival. We conclude that in a uniform population of untreated patients with diffuse large cell lymphoma, serum levels of IL-10 do not appear to have any prognostic value.
UR - http://www.scopus.com/inward/record.url?scp=0028933071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028933071&partnerID=8YFLogxK
U2 - 10.1182/blood.v85.9.2516.bloodjournal8592516
DO - 10.1182/blood.v85.9.2516.bloodjournal8592516
M3 - Article
C2 - 7537119
AN - SCOPUS:0028933071
SN - 0006-4971
VL - 85
SP - 2516
EP - 2520
JO - Blood
JF - Blood
IS - 9
ER -